Murphy, Middleton, Hinkle & Parker, Inc. Viking Therapeutics, Inc. Transaction History
Murphy, Middleton, Hinkle & Parker, Inc.
- $393 Million
- Q4 2025
A detailed history of Murphy, Middleton, Hinkle & Parker, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Murphy, Middleton, Hinkle & Parker, Inc. holds 1,706 shares of VKTX stock, worth $67,898. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,706Holding current value
$67,898% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
437Shares Held
66.6MCall Options Held
7.21MPut Options Held
3.87M-
Vanguard Group Inc Valley Forge, PA10MShares$398 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$240 Million0.01% of portfolio
-
State Street Corp Boston, MA4.51MShares$180 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.73MShares$148 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.58MShares$103 Million0.0% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...